HanAll Biopharma Co., Ltd. (KRX: 009420.KS), a global biopharmaceutical company committed to discovering and developing ...
Halozyme Therapeutics sees strong Q4 2024 growth, driven by ENHANZE platform royalties. Click here to find out why HALO stock ...
Zacks Investment Research on MSN2d
Can BIIB's New Drugs Revive Growth as Multiple Sclerosis Sales Fall?Sales of Biogen’s BIIB key multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and spinal muscular atrophy (SMA) treatment, Spinraza, are being hurt due to competitive pressure, which is ...
MedPage Today on MSN2d
Once-Yearly Lenacapavir PrEP a Safe, Promising Alternative to Twice-Yearly DosingA once-yearly intramuscular lenacapavir (Sunlenca) injection was safe and well-tolerated and had higher median levels of ...
GLP-1 receptor agonists (GLP-1RAs) were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management ...
On and off. In the world of Parkinson's disease, "on" is often used to communicate that medication is working and symptoms ...
During a live event, Alexander I. Spira, MD, PhD, and participants discuss efficacy, adverse events, and sequencing of EGFR-mutated NSCLC treatments.
Less than a year after CordenPharma earmarked a major chunk of change to beef up in peptide manufacturing for GLP-1s and ...
An oncologist from Atrium Health outlines how saving time administering immunotherapy could have far-reaching benefits.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback